HM
Howard Marks (Oaktree Capital) disclosed decreased in BIOXCEL THERAPEUTICS INC
Howard Marks (Oaktree Capital) filed a 13F change in BIOXCEL THERAPEUTICS INC (09075P204) on 2026-05-14, covering period end 2026-03-31.
Action
Decreased
Capital
$62,709 reported value
Institutional 13F Signals1 evidence source
Why it matters
This signal is anchored to the SEC filing date while retaining the underlying 13F period end.